TAVALISSE

Fostamatinib 100mg, Oral tablet

Grapefruit juice

· Severity: Moderate

· Notes for Consumers: These drugs may be taken together with close supervision from your prescriber. Taking these drugs together can increase the amount of Fostamatinib in your blood. Contact your health care provider if you experience diarrhea, signs of infection like fever or chills; cough; sore throat or pain or trouble passing urine, or signs of liver injury like dark yellow or brown urine; general ill feeling or flu-like symptoms; light-colored stools; loss of appetite, nausea; right upper belly pain; unusually weak or tired or yellowing of eyes and skin. Your doctor will monitor you for adverse effects and decrease your dose, if needed.

· Notes for Professionals: Monitor for fostamatinib toxicities that may require fostamatinib dose reduction (i.e., elevated hepatic enzymes, neutropenia, high blood pressure, severe diarrhea) if given concurrently with a strong CYP3A4 inhibitor. Concomitant use of fostamatinib with a strong CYP3A4 inhibitor increases exposure to the major active metabolite, R406, which may increase the risk of adverse reactions. R406 is extensively metabolized by CYP3A4; grapefruit juice is a strong CYP3A4 inhibitor. Coadministration of fostamatinib with another strong CYP3A4 inhibitor increased R406 AUC by 102% and Cmax by 37%.

<b>DISCLAIMER:</b><em> This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.</em>